Empagliflozin 25 mg tablet
Empagliflozin 25mg
Tablet · Prescription medication
Gujoo Pharmaceutical Co., Ltd.
MFDS item code 202102085 · Approved 2021.03.05
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to help control blood sugar in adult patients with type 2 diabetes. It can be administered alone, but if blood sugar control is difficult with monotherapy, it can be used in combination with other diabetes medications such as metformin. Additionally, it can be used alongside metformin and pioglitazone, sulfonylurea, or insulin therapy when blood sugar control is challenging. Caution is needed when prescribing this medication to patients with cardiovascular diseases and detailed clinical trial information should be referred to in professional materials. This medication helps improve blood sugar control, assisting in the management of diabetes.
The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. No dose adjustment is necessary for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well and whose glomerular filtration rate remains below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. This medicine should not be used in patients with end-stage renal disease (ESRD) or patients on dialysis, as efficacy is not expected. No dose adjustment is necessary for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment because it has not been studied in this population. No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiating treatment with this medicine is not recommended in patients aged 85 years or older because clinical experience is limited.
This medication should not be used in patients who are allergic to the active ingredient or its components. Additionally, it should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Patients with severely impaired kidney function, namely those with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2 or those with end-stage renal disease or on dialysis, should not receive this medication. This medication contains lactose; therefore, patients with genetic conditions such as lactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not use it. In patients with mildly impaired kidney function, the dosage of this medication should be adjusted or discontinued, and regular monitoring of kidney function is essential. In patients with mild to moderate heart failure, caution should be exercised when using this medication, and it is not recommended for patients with severe heart failure. When used with insulin or insulin secretagogues, there is a risk of hypoglycemia, and the dosages of these medications may need to be reduced. Patients should be aware that side effects such as hypoglycemia, urinary tract infections, genital infections, increased urination, and decreased fluid volume may occur while taking this medication. Particularly, severe metabolic acidosis known as ketoacidosis can occur, and immediate treatment should be sought if symptoms arise. Elderly patients or those at risk of fluid volume loss should be cautious as dehydration or hypotension may occur. Additionally, this medication may rarely cause serious infections such as genital necrosis; thus, if pain or swelling occurs around the genital area, medical personnel should be notified immediately. It is recommended that pregnant or breastfeeding women do not use this medication, and if pregnancy is confirmed, cessation of treatment should occur. The safety and efficacy in children under 18 years of age have not been established. In case of overdose, appropriate treatment should be initiated based on clinical conditions, and this medication may increase urine output. This medication may interact with other drugs, so if other medications are being taken, healthcare providers should be informed. Caution is necessary while driving or operating machinery due to the risk of hypoglycemia. Regular monitoring of kidney function and blood sugar levels is important while on this medication.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture, at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's efficacy and safety.
Pale yellow, double-convex, oval, film-coated tablet
10 tablets/box [10 tablets/PTP x 1], 30 tablets/box [10 tablets/PTP x 3], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 25mg
Tablet · Prescription medication
Gujoo Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.